Empagliflozin may reduce CKD in patients with type 2 diabetes


eMediNexus    05 November 2017

Findings of a post hoc analysis of the EMPA REG OUTCOME trial show that treatment with empagliflozin may reduce chronic kidney disease CKD in patients with type 2 diabetes and established cardiovascular disease. These findings were reported at ASN Kidney Week 2017 in New Orleans

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.